VSL#3 ( DrugBank: - )

4 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
96	クローン病	7
97	潰瘍性大腸炎	3
107	若年性特発性関節炎	1
291	ヒルシュスプルング病（全結腸型又は小腸型）	1

96. クローン病

臨床試験数 : 2,400 / 薬物数 : 1,391 - (DrugBank : 267) / 標的遺伝子数 : 170 - 標的パスウェイ数 : 215

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01765439 (ClinicalTrials.gov)	February 2014	7/1/2013	The Effect of VSL#3 Probiotic Preparation on the Bile Acid Metabolism in Patients With Inflammatory Bowel Disease	The Effect of VSL#3 (Original De Simone Formulation) Probiotic Preparation on the Bile Acid Metabolism in Patients With Inflammatory Bowel Disease	Crohn Disease;Ulcerative Colitis	Dietary Supplement: VSL#3 (Original De Simone formulation)	Charles University, Czech Republic	Iscare i.v.f., Czech Republic;CD Investments srl;University Of Perugia;University of Roma La Sapienza	Active, not recruiting	N/A	N/A	All	79	N/A	Czechia;Czech Republic
2	NCT01632462 (ClinicalTrials.gov)	September 2012	25/6/2012	A Prospective, Placebo Controlled, Double-Blind, Cross-over Study on the Effects of a Probiotic Preparation (VSL#3) on Metabolic Profile, Intestinal Permeability, Microbiota, Cytokines and Chemokines Expression and Other Inflammatory Markers in Pediatric Patients With Crohn's Disease	A Prospective, Placebo Controlled, Double-Blind, Cross-over Study on the Effects of a Probiotic Preparation (VSL#3) on Metabolic Profile, Intestinal Permeability, Microbiota, Cytokines and Chemokines Expression and Other Inflammatory Markers in Pediatric Patients With Crohn's Disease	Crohn's Disease	Drug: VSL#3	Federico II University	NULL	Recruiting	5 Years	17 Years	Both	30	Phase 4	Italy
3	NCT01548014 (ClinicalTrials.gov)	January 2010	17/2/2012	The Effect of a Probiotic Preparation (VSL#3) Plus Infliximab in Children With Crohn's Disease	Reduction in Frequency of Infliximab Administration From q 8 Weeks to q 12 Weeks in Children With Crohn's Disease Receiving Probiotic VSL#3 Supplementation: A Pilot Study	Crohn's Disease	Dietary Supplement: VSL#3	Samsung Medical Center	NULL	Recruiting	13 Years	17 Years	Both	1	Phase 3	Korea, Republic of
4	NCT00367705 (ClinicalTrials.gov)	August 2009	22/8/2006	VSL#3 Treatment in Children With Crohn's Disease	Double-blind Placebo Controlled Trial of VSL#3 in Children With Crohn's Disease	Crohn's Disease	Dietary Supplement: VSL#3®;Dietary Supplement: Placebo	Hadassah Medical Organization	NULL	Not yet recruiting	6 Years	18 Years	Both	300	Phase 4	Israel
5	NCT00944736 (ClinicalTrials.gov)	July 2009	22/7/2009	Effect of VSL#3 on Intestinal Permeability in Pediatric Crohn's Disease	Effect of Probiotic VSL#3 on Intestinal Permeability of Pediatric Patients With Crohn's Disease in Remission	Crohn's Disease	Dietary Supplement: VSL#3;Dietary Supplement: Placebo	Children's Mercy Hospital Kansas City	VSL Pharmaceuticals	Completed	11 Years	17 Years	Both	12	Phase 3	United States
6	NCT00114465 (ClinicalTrials.gov)	June 2005	14/6/2005	VSL#3 Versus Placebo in Maintenance of Remission in Crohn's Disease	Randomized, Double-Blind, Placebo-Controlled Study of VSL#3 Versus Placebo in the Maintenance of Remission in Crohn's Disease	Crohn's Disease	Drug: VSL#3;Other: Placebo	Orphan Australia	NULL	Completed	18 Years	75 Years	Both	38	Phase 4	Australia
7	NCT00175292 (ClinicalTrials.gov)	December 2003	13/9/2005	A Randomized Controlled Trial of VSL#3 for the Prevention of Endoscopic Recurrence Following Surgery for Crohn's Disease.	A Randomized and Placebo-Controlled Double-Blind Multicentre Study to Determine the Efficacy and Safety of VSL#3 Probiotic Food Supplement Mixture in Prevention of Endoscopic Recurrence in Crohn's Disease Patients With Ileocolonic Surgical Resection and Small Intestine to Colon Anastomosis.	Crohn's Disease;Inflammatory Bowel Disease	Drug: Probiotic - VSL#3	University of Alberta	Canadian Institutes of Health Research (CIHR)	Completed	16 Years	N/A	Both	120	Phase 3	Canada

先頭へ

97. 潰瘍性大腸炎

臨床試験数 : 2,527 / 薬物数 : 1,465 - (DrugBank : 259) / 標的遺伝子数 : 144 - 標的パスウェイ数 : 202

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03415711 (ClinicalTrials.gov)	April 28, 2017	5/1/2018	PRObiotic VSL#3® for Maintenance of Clinical and Endoscopic REMission in Ulcerative Colitis	A Double-blind, Randomized, Placebo-controlled, Single-center, Dose-finding, Pilot Study Evaluating the Efficacy of VSL#3® in the Maintenance of Clinical and Endoscopic Remission of Mild-to-moderate UC	Ulcerative Colitis	Dietary Supplement: VSL#3®;Drug: Mesalamine;Drug: Placebo	VSL Pharmaceuticals	Actial Farmaceutica S.r.l.	Terminated	18 Years	85 Years	All	14	N/A	Italy
2	NCT01765439 (ClinicalTrials.gov)	February 2014	7/1/2013	The Effect of VSL#3 Probiotic Preparation on the Bile Acid Metabolism in Patients With Inflammatory Bowel Disease	The Effect of VSL#3 (Original De Simone Formulation) Probiotic Preparation on the Bile Acid Metabolism in Patients With Inflammatory Bowel Disease	Crohn Disease;Ulcerative Colitis	Dietary Supplement: VSL#3 (Original De Simone formulation)	Charles University, Czech Republic	Iscare i.v.f., Czech Republic;CD Investments srl;University Of Perugia;University of Roma La Sapienza	Active, not recruiting	N/A	N/A	All	79	N/A	Czechia;Czech Republic
3	NCT00951548 (ClinicalTrials.gov)	October 2006	2/8/2009	Food Supplementation With VSL#3 as a Support to Standard Pharmaceutical Therapy in Ulcerative Colitis	Food Supplementation With the Probiotic Preparation VSL#3 as a Support to Standard Pharmaceutical Therapy in Patients With Mild to Moderate Active Ulcerative Colitis. A Double-blind, Randomized, Placebo Controlled Study	Ulcerative Colitis	Dietary Supplement: VSL#3;Dietary Supplement: Placebo	VSL Pharmaceuticals	NULL	Completed	18 Years	N/A	Both	144	N/A	Italy

107. 若年性特発性関節炎

臨床試験数 : 441 / 薬物数 : 282 - (DrugBank : 56) / 標的遺伝子数 : 52 - 標的パスウェイ数 : 142

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03092427 (ClinicalTrials.gov)	September 4, 2017	21/3/2017	Evaluation of the Effectiveness of a Probiotic Treatment on Clinical Activity, Relapse Rates and Modification of the Intestinal Microbiota in Patients With Juvenile Idiopathic Arthritis (JIA)	Evaluation of the Effectiveness of a Probiotic Treatment on Clinical Activity, Relapse Rates and Modification of the Intestinal Microbiota in Patients With Juvenile Idiopathic Arthritis (JIA)	Juvenile Idiopathic Arthritis	Dietary Supplement: VSL#3;Other: Placebo	Assistance Publique - Hôpitaux de Paris	NULL	Active, not recruiting	1 Year	7 Years	All	51	N/A	France

291. ヒルシュスプルング病（全結腸型又は小腸型）

臨床試験数 : 14 / 薬物数 : 35 - (DrugBank : 15) / 標的遺伝子数 : 0 - 標的パスウェイ数 : 0

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00630838 (ClinicalTrials.gov)	September 2006	28/2/2008	Probiotic Prophylaxis of Hirschprung's Disease Associated Enterocolitis (HAEC)	Probiotic Prophylaxis of Hirschprung's Disease Associated Enterocolitis (HAEC)	Hirschsprung Disease	Drug: VSL#3;Drug: Placebo	University of Michigan	NULL	Completed	1 Month	12 Months	All	62	Phase 2	United States

先頭へ